Financials
Financial year 2025
SYNAPHARM INDUSTRIAL SYNTHESIS from Grâce-Hollogne, company number BE0465726791, closed financial year 2025 with a result of € 1.9 million after tax. For that financial year SYNAPHARM INDUSTRIAL SYNTHESIS recorded a gross margin of € 2.7 million and equity of € 3.7 million. Compared with financial year 2024, the result moved from € 456,662 to € 1.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 17, 2026.
€ 3.7 million
▲ 102% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.9 million
▲ € 1.4 million vs 2024
Profit after tax over the fiscal year.
€ 2.3 million
▲ 128% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.6 million.
People and assets in 2025
1.7
Average over the fiscal year, from the social balance sheet.
€ 79,926
▲ € 77,318 vs 2024
€ 47,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 30,408
▲ € 28,617 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 48,668
▼ 17% vs 2024
€ 10,189 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 2.1 million
▲ 200% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 169,710
▲ 7% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 452,624 | € 875,101 | € 664,791 | € 2,687,175 | ▲ € 2 million |
| Profit after taxes | € 264,029 | € 646,617 | € 456,662 | € 1,871,976 | ▲ € 1.4 million |
| Equity | € 731,529 | € 1,378,146 | € 1,834,808 | € 3,706,784 | ▲ 102% |
| Total debts | € 719,283 | € 1,322,124 | € 960,381 | € 2,355,668 | ▲ 145% |
| Cash | € 639,466 | € 168,604 | € 1,027,899 | € 2,346,920 | ▲ 128% |
| Retained profit | € 631,529 | € 1,278,146 | € 1,734,808 | € 3,606,784 | ▲ 108% |
| Dividend | € 67,084 | € 0 | € 0 | € 0 | |
| Bank debt | € 77,879 | € 68,363 | € 58,628 | € 48,668 | ▼ 17% |
| Balance sheet total | € 1,500,812 | € 2,700,270 | € 2,795,189 | € 6,062,451 | ▲ 117% |
| Employees (FTE) | 1.8 | 1.8 | - | 1.7 |
Key figures of SYNAPHARM INDUSTRIAL SYNTHESIS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SYNAPHARM INDUSTRIAL SYNTHESIS?
What happened at SYNAPHARM INDUSTRIAL SYNTHESIS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jennifer Gu stepped down as director. NBB
- Mark Thurston stepped down as director. NBB
- YSAPSYN stepped down as director. NBB
- BRANDON LEE stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 1.9 million (▲ € 1.4 million vs 2024). Source: NBB ↗
- BRANDON LEE became a director. NBB
- Edward Lee stepped down as director. NBB
- Artesyn stepped down as director. NBB
In short
From € 264,029 profit in 2022 to € 1.9 million profit in 2025.
Paid € 1 million in corporate taxes since 2022.
Best year ever: 2025, with € 1.9 million profit.
On average € 1.6 million of value added per employee in 2025.
A new publication or filing at SYNAPHARM INDUSTRIAL SYNTHESIS? We notify you, reason included.
Follow SYNAPHARM INDUSTRIAL SYNTHESISDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of YSAPSYN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
SYNAPHARM INDUSTRIAL SYNTHESISThe shares are held by YSAPSYN (10%).
Directors
According to the 2025 annual accounts
Edward Lee
Director
since 2024 · until 2026
since 2024 · until 2025
Jennifer Gu
Director
since 2024 · until 2030
Mark Thurston
Director
since 2024 · until 2030
since 2025 · until 2030
BRANDON LEE
Director
since 2026 · until 2030
Shareholders
10%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue de l'Aéroport 52
4460 Grâce-Hollogne
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →DIGITAL LEAD
€ 245,436 gross margin · 2024
DL INVEST
Athina Logistics
€ 1.4 million gross margin · 2025
LOGISTICS IN WALLONIA
€ 654,385 gross margin · 2025
Munlogistic
€ 17,923 gross margin · 2025
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0465.726.791
- VAT number
- BE 0465.726.791
- Registered office
- Rue de l'Aéroport 52, 4460 Grâce-Hollogne
- Names & denominations
- SYNAPHARM INDUSTRIAL SYNTHESIS · S.I.S.
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 March 1999
- Peppol
- Active · Active since 20 Jan 2026
- Activities · NACE
Vervaardiging van andere organische chemische basisproducten
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Vervaardiging van overige organische chemische basisproducten